Jonathan Young is COO at Akero Therapeutics, Inc. (AKRO). They have made 23 open-market trades across 1 company since 2021, most recently 2025-12-09.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 23 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKRO | SELL · 10b5-1 | 2025-10-01 | 2025-10-03 | $47.75 | $1.2M | +16.3% | +17.4% | N/A |
| AKRO | SELL | 2025-09-11 | 2025-09-12 | $43.02 | $25K | +9.8% | +24.1% | N/A |
| AKRO | SELL · 10b5-1 | 2025-09-02 | 2025-09-04 | $46.28 | $705K | -4.7% | +3.0% | +22.3% |
| AKRO | SELL · 10b5-1 | 2025-08-12 | 2025-08-13 | $47.78 | $1.2M | -1.5% | -9.0% | +13.6% |
| AKRO | SELL | 2025-06-18 | 2025-06-20 | $54.84 | $159K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL | 2025-06-10 | 2025-06-12 | $53.99 | $269K | +5.5% | +1.0% | -17.1% |
| AKRO | SELL | 2025-03-12 | 2025-03-14 | $44.88 | $27K | -1.9% | -14.8% | +21.3% |
| AKRO | SELL · 10b5-1 | 2025-03-04 | 2025-03-05 | $44.86 | $4.5M | +0.6% | -17.6% | +15.8% |
| AKRO | SELL · 10b5-1 | 2025-02-03 | 2025-02-05 | $53.81 | $538K | -13.4% | -26.3% | -26.4% |
| AKRO | SELL · 10b5-1 | 2025-01-02 | 2025-01-06 | $28.03 | $280K | -9.4% | +107.5% | +29.7% |
| AKRO | SELL | 2024-12-10 | 2024-12-12 | $30.79 | $154K | +0.0% | -20.7% | +60.6% |
| AKRO | SELL · 10b5-1 | 2024-12-02 | 2024-12-04 | $32.13 | $321K | -4.9% | -8.2% | +44.8% |
| AKRO | SELL · 10b5-1 | 2024-11-01 | 2024-11-05 | $31.57 | $3.2M | -17.5% | -12.7% | +58.2% |
| AKRO | SELL · 10b5-1 | 2024-10-14 | 2024-10-16 | $30.15 | $1.2M | -4.3% | -9.5% | -29.5% |
| AKRO | SELL · 10b5-1 | 2024-10-01 | 2024-10-03 | $28.18 | $282K | +7.2% | +14.8% | +0.5% |
| AKRO | SELL | 2024-09-10 | 2024-09-13 | $26.18 | $15K | +2.2% | +9.5% | +5.9% |
| AKRO | SELL · 10b5-1 | 2024-09-03 | 2024-09-05 | $26.59 | $232K | +0.3% | +0.7% | +16.4% |
| AKRO | SELL · 10b5-1 | 2024-08-01 | 2024-08-02 | $26.75 | $268K | +1.2% | +10.7% | +31.4% |
| AKRO | SELL · 10b5-1 | 2024-07-01 | 2024-07-02 | $23.40 | $117K | +23.5% | +18.6% | +29.1% |
| AKRO | SELL | 2024-06-11 | 2024-06-13 | $22.64 | $114K | -5.2% | +13.4% | +5.9% |
| AKRO | SELL · 10b5-1 | 2024-06-03 | 2024-06-05 | $19.29 | $96K | +10.1% | +3.1% | +25.0% |
| AKRO | SELL · 10b5-1 | 2024-05-01 | 2024-05-02 | $20.15 | $101K | -0.1% | -5.6% | +31.5% |
| AKRO | SELL · 10b5-1 | 2024-04-01 | 2024-04-03 | $24.36 | $234K | -7.1% | -15.9% | -4.3% |
| AKRO | SELL | 2024-03-13 | 2024-03-15 | $28.33 | $18K | -9.3% | -19.4% | -8.6% |
| AKRO | SELL | 2023-12-27 | 2023-12-29 | $24.00 | $130K | -2.0% | +2.3% | +9.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.